Mindpath Health

Mindpath Health in Davis, California offers Spravato (esketamine) for adults with treatment-resistant depression who have not found sufficient relief through psychiatry and therapy alone. Spravato is the only FDA-approved, self-administered nasal spray for treatment-resistant depression, commonly prescribed alongside antidepressant medications and therapy.

Spravato is self-administered twice weekly under clinician supervision, with patients observed in-office for two hours after each dose. After the first four weeks, the clinician determines the appropriate ongoing schedule.

National data shows about half of esketamine patients report at least a 50% improvement in depressive symptoms. Alongside Spravato, the Davis office offers TMS, psychiatry, medication management, and therapy, and is in-network with most major commercial insurance plans in California.